These key learning points summarize the consensus- and evidence-based recommendations included in this edition. The sources listed here for each statement recommend that physicians perform or implement these actions directly in a clinical setting. A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patientoriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afp/2004/0201/p548.html.

1. Screen patients 21 to 29 years of age for cervical cancer with a cervical cytology (Papanicolaou) test every 3 years
Evidence Rating: SORT A
Source: Section One, references 14 and 15

 2. Screen average-risk patients ages 30 to 65 years for cervical cancer with a cytology test every 3 years, with a US Food and Drug Administration-approved primary high-risk human papillomavirus (HPV) test every 5 years, or with cotesting (cytology test and high-risk HPV test) every 5 years.
Evidence rating: SORT A
Source: Section One, references 14, 15, 16, and 18

 3. Any patient with new onset of postmenopausal bleeding should have a workup, including up-to-date cervical cancer screening, bimanual and speculum examinations, and if indicated, testing for sexually transmitted infections. First-line diagnostic tests include transvaginal ultrasonography to measure endometrial thickness and endometrial biopsy.
Evidence rating: SORT C
Source: Section Two, references 5, 8, 12, and 13